HomeBOT • ASX
Botanix Pharmaceuticals Ltd
add
Market news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (AUD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 188.80K | -0.09% |
Operating expense | 15.57M | 532.16% |
Net income | -15.44M | -464.98% |
Net profit margin | -8.18K | -465.47% |
Earnings per share | — | — |
EBITDA | -15.43M | -459.15% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (AUD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 48.44M | 164.49% |
Total assets | 99.45M | 108.57% |
Total liabilities | 6.96M | 203.76% |
Total equity | 92.49M | — |
Shares outstanding | 1.82B | — |
Price to book | 7.20 | — |
Return on assets | -40.19% | — |
Return on capital | -42.81% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (AUD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -15.44M | -464.98% |
Cash from operations | -15.28M | -712.75% |
Cash from investing | -426.99K | 94.22% |
Cash from financing | 200.20K | -98.50% |
Net change in cash | -15.44M | -482.88% |
Free cash flow | -4.57M | 45.34% |
Previous close
$0.36
Day range
$0.37 - $0.38
Year range
$0.21 - $0.54
Market cap
687.27M AUD
Avg Volume
11.14M
P/E ratio
-
Dividend yield
-
Primary exchange
ASX
About
Botanix Pharmaceuticals is listed on the Australian Securities Exchange with the issue code BOT. The Company is headquartered in Perth, Western Australia and Philadelphia, USA. It is a clinical stage synthetic cannabinoid company, focusing on the compound Cannabidiol. The company has two separate development platforms, dermatology and antimicrobial. Botanix also has an exclusive license to use a proprietary drug delivery system Permetrex, for direct skin delivery of active pharmaceuticals which is utilised in all of their programs. Wikipedia
Founded
1984
Website
Employees
11
